A detailed history of Sheets Smith Wealth Management transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Sheets Smith Wealth Management holds 6,848 shares of HALO stock, worth $426,767. This represents 0.04% of its overall portfolio holdings.

Number of Shares
6,848
Holding current value
$426,767
% of portfolio
0.04%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 30, 2024

BUY
$37.81 - $52.4 $258,922 - $358,835
6,848 New
6,848 $358,000
Q4 2022

Mar 08, 2023

BUY
$40.06 - $59.44 $182,913 - $271,403
4,566 New
4,566 $259,000
Q3 2021

Oct 15, 2021

SELL
$38.47 - $46.42 $182,655 - $220,402
-4,748 Closed
0 $0
Q2 2021

Aug 03, 2021

BUY
$38.84 - $51.31 $184,412 - $243,619
4,748 New
4,748 $216,000
Q1 2021

Apr 23, 2021

SELL
$39.51 - $51.45 $187,593 - $244,284
-4,748 Closed
0 $0
Q4 2020

Jan 13, 2021

BUY
$25.81 - $43.62 $122,545 - $207,107
4,748 New
4,748 $203,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $8.68B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Sheets Smith Wealth Management Portfolio

Follow Sheets Smith Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sheets Smith Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Sheets Smith Wealth Management with notifications on news.